Boutique Biotech previously covered Affimed (AFMD) as part of an ongoing series (part I, part II, and part III). With the ASH meeting coming up on the near horizon, this post will cover a few updates announced by the company last week. Overall, not very much was shared, which was surprising given our expectation of AFM13+NK data from MD Anderson study. …
© 2024 Bohdan (Bo) Khomtchouk, Ph.D.
Substack is the home for great culture